ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Tae Gyun Kwon
No relevant relationships to disclose
Seo Seong
No relevant relationships to disclose
Seok-Soo Byun
No relevant relationships to disclose
Hideaki Miyake
No relevant relationships to disclose
Takeshi Ueda
No relevant relationships to disclose
Dingwei Ye
No relevant relationships to disclose
Jesús García-Donas
Consultant or Advisory Role - Pfizer
Marine Gross-Goupil
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Thomas E. Hutson
No relevant relationships to disclose
Robert DeBenedetto
Employment or Leadership Position - SFJ Pharmaceuticals Group
Stock Ownership - SFJ Pharmaceuticals Group
Subramanian Hariharan
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Min Young Lee
Employment or Leadership Position - SFJ Pharmaceuticals Group
Rolf Gerhard Linke
Employment or Leadership Position - SFJ Pharmaceuticals Group
Fumito Tsuji
Employment or Leadership Position - SFJ Pharmaceuticals Group
David I. Quinn
Consultant or Advisory Role - SFJ Pharmaceuticals Group